Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Mavenclad
Pharma
Merck KGaA expects Mavenclad generics to deal serious blow in US
After delivering solid growth in 2025, Germany’s Merck KGaA expects an onslaught of U.S. generics to its MS blockbuster Mavenclad this year.
Fraiser Kansteiner
Mar 5, 2026 11:30am
Merck KGaA tweaks 2025 forecast as geopolitical concerns mount
May 15, 2025 1:20pm
Selma Blair joins EMD Serono campaign for MS drug Mavenclad
Feb 20, 2025 1:11pm
Merck KGaA, analysts share optimism about potential CDMO rebound
Aug 7, 2024 3:13pm
After pulling Lumoxiti in Europe, AstraZeneca does same in US
Jan 13, 2023 10:15am
Merck KGaA launches first-ever TV ad for MS med Mavenclad
Jul 19, 2021 7:32am
